ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Sees Significant Decrease in Short Interest

Posted by Joseph Casey on Jul 30th, 2026

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report) saw a significant drop in short interest in July. As of July 15th, there was short interest totaling 57,777 shares, a drop of 40.1% from the June 30th total of 96,526 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average daily volume of 68,640 shares, the days-to-cover ratio is presently 0.8 days.

ALPS Medical Breakthroughs ETF Price Performance

Shares of SBIO stock traded up $2.06 on Thursday, hitting $65.20. The stock had a trading volume of 17,842 shares, compared to its average volume of 37,469. ALPS Medical Breakthroughs ETF has a twelve month low of $32.35 and a twelve month high of $69.34. The company has a fifty day moving average price of $59.23 and a two-hundred day moving average price of $54.73.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp bought a new stake in shares of ALPS Medical Breakthroughs ETF in the first quarter worth about $782,000. Raymond James Financial Inc. bought a new position in shares of ALPS Medical Breakthroughs ETF during the 2nd quarter valued at about $82,000. Comerica Bank acquired a new position in shares of ALPS Medical Breakthroughs ETF in the 3rd quarter valued at approximately $27,000. Virtu Financial LLC acquired a new position in shares of ALPS Medical Breakthroughs ETF in the 3rd quarter valued at approximately $650,000. Finally, Silver Oak Securities Incorporated acquired a new position in shares of ALPS Medical Breakthroughs ETF in the 4th quarter valued at approximately $677,000.

ALPS Medical Breakthroughs ETF Company Profile

(Get Free Report)

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.